Drug Watch

Drug Watch

The latest on the biggest pipeline moves.

JUVÉDERM VOLUX XC approved by FDA for jawline definition
August 03, 2022

Allergan Aesthetics announced the US Food and Drug Administration has approved the hyaluronic acid filler for jawline definition improvement.

FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis
July 29, 2022

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

Alopecia Areata Gets FDA-Approved Drug
July 27, 2022

Approval of a novel oral JAK inhibitor specifically indicated for this challenging condition fills a long unmet need.

Stephen Stripling, MD, FAAP, Discusses Study of Berdazimer Gel for Molluscum Contagiosum
July 21, 2022

Results published in the Journal of the American Medical Association (JAMA) Dermatology detailed the efficacy and safety of berdazimer gel 10.3%, in the treatment of molluscum contagiosum.

NIH Launches mRNA Nipah Vaccine Clinical Trial
July 15, 2022

An early-stage clinical trial will evaluate an investigational vaccine to prevent Nipah virus infection.

FDA Approves Noblepharma’s Sirolimus Topical Gel 0.2%
July 14, 2022

The groundbreaking approval of sirolimus topical gel brings relief to patients with facial angiofibroma related to tuberous sclerosis complex with the first FDA-approved topical treatment.

How Dupixent Improves Moderate-to-Severe AD in Adult and Pediatric Patients
July 06, 2022

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.

FDA Issues Third CRL in 2 years to Verrica Pharmaceuticals
July 05, 2022

Verrica is complying with the FDA through 3 Complete Response Letters to achieve the first FDA-approved treatment of molluscum contagiosum.

Managing Complex Diseases with Therapeutic Monitoring Program
June 28, 2022

Complex diseases can be difficult to manage for optimal outcomes. Monitoring programs of therapies can help with that management

Pointers with Dr Portela: New FDA Treatment for Alopecia Areata
June 22, 2022

In this week’s Pointers with Dr Portela, the 208SkinDoc talks the newest approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata.